Trials / Completed
CompletedNCT02369172
Drug-Drug Interaction Study: ASP2151 and Bupropion
A Single-centre, Open-label Study in Healthy Men to Investigate the Effect of Repeated Oral Doses of ASP2151 on the Pharmacokinetics of Bupropion
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Maruho Europe Limited · Industry
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
CYP2B6 is involved in the metabolism of many drugs. So, it is important to assess in vivo the effect of ASP2151 on that enzyme to determine any possible drug interactions. The aim of this trial is to investigate the potential for interaction of ASP2151 with the CYP2B6 probe substrate bupropion.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bupropion | |
| DRUG | ASP2151 |
Timeline
- Start date
- 2015-02-01
- Primary completion
- 2015-04-01
- Completion
- 2015-04-01
- First posted
- 2015-02-23
- Last updated
- 2019-02-21
- Results posted
- 2019-01-15
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT02369172. Inclusion in this directory is not an endorsement.